全球药企龙头正在中国押下重注。阿斯利康宣布在华投资25亿美元,拟在北京建立第六个全球战略研发中心,与和铂医药(2142.HK)、元思生肽、康泰生物(300601.SZ)三家生物科技企业达成合作。这已不是和铂医药与阿斯利康的首次合作——双方曾分别在2022年、2024年就抗体项目展开授权合作。此次合作更为深入。阿斯利康将以每股10.74港币的价格认购和铂医药增发的9.15%股份,认购价较3月21日...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.